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Abstract: Inertial measurement units (IMUs) allow accurate quantification of gait impairment of
people with multiple sclerosis (pwMS). Nonetheless, it is not clear how IMU-based metrics might
be influenced by pragmatic aspects associated with clinical translation of this approach, such as
data collection settings and gait protocols. In this study, we hypothesised that these aspects do
not significantly alter those characteristics of gait that are more related to quality and energetic
efficiency and are quantifiable via acceleration related metrics, such as intensity, smoothness, stability,
symmetry, and regularity. To test this hypothesis, we compared 33 IMU-based metrics extracted
from data, retrospectively collected by two independent centres on two matched cohorts of pwMS.
As a worst-case scenario, a walking test was performed in the two centres at a different speed along
corridors of different lengths, using different IMU systems, which were also positioned differently.
The results showed that the majority of the temporal metrics (9 out of 12) exhibited significant
between-centre differences. Conversely, the between-centre differences in the gait quality metrics
were small and comparable to those associated with a test-retest analysis under equivalent conditions.
Therefore, the gait quality metrics are promising candidates for reliable multi-centric studies aiming
at assessing rehabilitation interventions within a routine clinical context.
Keywords: multiple sclerosis; gait metrics; wearable sensors; test-retest reliability; sampling
frequency; accelerometry; autocorrelation; harmonic ratio; six-minute walk
1. Introduction
Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system affecting
2.3 million people worldwide [1]. MS is the major non-traumatic cause of disability in young and
middle-aged adults [2], with a significant negative impact on independence and social participation [3].
Walking impairment is one of the most common functional deficits due to MS, even in the early stages
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of the disease [4]. Importantly, nearly 70% of people with MS (pwMS) reported that walking difficulty
is the most challenging aspect of their condition [5].
Given the high impact of gait impairment on pwMS, different rehabilitation interventions focused
on improving locomotion are currently applied to improve the quality of life in this population [6]. The
effects of these interventions, togetherwith the progression of the disease, are usually assessed in clinical
practice using clinical scales, such as the expanded disability status scale (EDSS) [7] or timed tests,
such as the timed up and go test (TUG) [8], the timed 25-foot walk test (T25FW) [9], and the 6-minute
walk test (6MWT) [10]. Although widely used, these tests suffer from some limitations. Firstly, they
assess only the time taken to execute the test (e.g., TUG and T25FW) or the distance travelled in a given
time (6 min for the 6MWT), without providing objective measures of the different components and
characteristics of the task that could be useful to describe how the performance is possibly impaired [11].
Secondly, these clinical tests have a relatively limited sensitivity to change [9,12,13] and a flooring
effect [9,14] that makes it difficult to detect possible alterations in minimally impaired pwMS [15–17].
Instrumental methods may partly overcome these limitations by providing additional quantitative
information for a more complete characterisation of walking, which can be useful to tailor the
rehabilitative intervention and objectively assess its effects [11,18]. In particular, wearable inertial
measurement units (IMUs), including accelerometers, gyroscopes, and magnetometers, represent
cost-effective tools to perform objective assessments of walking in pwMS outside movement analysis
labs [19,20], and even during free-living and community contexts [21,22]. IMUs have been widely used
to analyse different locomotor tasks in pwMS, such as straight-line over ground [17,23–27] and treadmill
walking [28], standing up, walking, turning, and sitting down (e.g., the TUG) [15,29], walking with
head turns and over/around obstacles [30,31], walking while texting [32], and stairway walking [33].
During these tests, several parameters have been extracted from IMUs, including spatio-temporal
parameters [15,24,27,28,31,32,34], indexes of gait variability and stability [17,23,24,26,31,33], trunk
sway metrics [15,23,30,34], and angular variables [15,25,27,34]. Nonetheless, what does not yet clearly
emerge from current literature on pwMS is which of these could be more reliably adopted within the
clinical context.
Besides the issue of identifying among the above metrics those that are more capable of
characterising the disease progression, hence providing similar results for patients with similar
clinical conditions, and that have the sensitivity to detect changes associated with clinical interventions,
the clinical adoption of specific gait metrics also requires accounting for a number of pragmatic
limitations associated with testing conditions. These include an understanding of which output is more
robust to testing site characteristics (e.g., corridor lengths, lightening, noise, etc.), adopted measuring
instruments and their configuration (e.g., brand, location on the body, sampling frequency) [35–37],
type of gait test (e.g., a single pass, a 1-minute or a 6MWT), or instructions given to patients (e.g.,
self-selected or fast walking speed, use or not use of an assistive device) [28,38–45]. All these aspects are
particularly difficult to standardise in a busy clinical environment and most likely occur in combination
with each other.
The aim of this study was to identify those gait metrics that provide equivalent assessment of
pwMS with similar characteristics in terms of age, gender, and gait disability, despite these being
tested in different centres and in non-standardised conditions. Our hypothesis was that while pwMS
might be able to adjust their gait in terms of spatio-temporal parameters in response to different testing
conditions (e.g., if asked to increase their speed), they would not be able to control those aspects of gait
more related to its overall quality and energetic efficiency [46,47]. As a result, metrics extracted directly
from the acceleration signals and representative of intensity, smoothness, stability, symmetry, and
regularity were expected to be more robust to differences in the test settings. To verify this hypothesis,
we compared retrospective data from two matched cohorts of pwMS, which were collected by two
independent hospitals using protocols that differed for: (i) brand, size, and sampling frequency of the
IMUs; (ii) IMU positioning; (iii) subject instructing; (iv) length of the path. As a term of reference, we
also compared differences in IMU-based metrics between the two centres (between-centre differences)
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to those observable between two sessions performed by the same centre (between-day test-retest
reliability).
2. Materials and Methods
2.1. Participants
Two research centres, one located in Italy (centre A) and one in the United Kingdom (centre B),
provided retrospective IMUdata collectedwhile pwMSwalked back and forth for 6min along a hospital
corridor. The patients’ level of disability was assessed with the EDSS scale, scored by an experienced
neurologist. Patients were excluded if not free from any orthopaedic and/or musculoskeletal and
neurological disorders other than MS that may have affected their gait and balance. Since there were
no restrictions for MS subtypes, both patients with relapsing remitting MS who were relapse-free for
30 days prior to assessment (centre A) and patients with secondary progressive MS (centre B) were
included in the study. Thirteen pwMS were selected from each data set to form two cohorts, with
individual patients matched if having the same age, gender, EDSS score, and type of assistive device
(Table 1). As a result of this matching, the sample size, percentage of females, EDSS score distribution,
number of pwMS who required an assistive device, and type of assistive device used during the
walking test were the same in the two centres. The average walking speed was calculated as the total
distance walked during the test divided by the duration of the walking trial.
Table 1. Clinical characteristics of peoplewithmultiple sclerosis for centreA and centre B. Abbreviations:
expanded disability status scale (EDSS); people with multiple sclerosis (pwMS); Mann-Whitney U
(MWU) statistic; p-value (p); chi-square (X2).
Centre A
(n = 13)
Centre B
(n = 13)
Statistics
Age [years] 51 (35–63) 57 (34–64) U = 58, p = 0.18
Gender [men/women] 3/10 3/10 X2(1) = 0.00, p = 1.00
EDSS score (0–10) 4.5 (2.0–6.5) 4.5 (2.5–6.5) U = 83, p = 0.93
Mild (2.0–2.5) 1 1
Moderate (3.0–4.5) 6 6
Severe (5.0–6.5) 6 6
Assistive devices
Walker 1 pwMS 1 pwMS –
Cane 2 pwMS 2 pwMS –
Walking speed [m/s] 1.1 (0.5–1.4) 0.7 (0.4–1.0) U = 31, p < 0.01 *
Values are median (range) or numbers. * p < 0.05.
pwMS from centre B repeated the instrumented walking test on a second visit, which was held
7–14 days after the first test at the same time of the day. The testing procedures were also kept constant
between the two sessions. These data were used to assess between-day test-retest reliability.
Institutional review boards or ethics committees at the institutions in each country approved the
separate protocols (NRES Committee Yorkshire & The Humber-Bradford Leeds (reference 15/YH/0300)
and Ethical Committee of Don Carlo Gnocchi Foundation, Milan, Italy, references 29-03-2017 and
13-02-2019). Written informed consent was provided by all subjects. Data were collected in accordance
with the International Declaration of Helsinki.
2.2. Experimental Protocol
Acceleration and angular velocity data from three IMUs, located at the fifth lumbar vertebra and
around the right and left ankles, were recorded in both centres while pwMS walked back and forth
for 6 min along a straight corridor free of obstacles and other people. If needed, they could use an
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assistive device and take short resting breaks while standing. Each IMU was manually aligned along
the anatomical antero-posterior (AP), medio-lateral (ML), and vertical (V) axes.
The differences between the experimental protocols followed by centre A and centre B were:
(i) device manufacturers and sampling frequency used to record acceleration and angular velocity
signals; (ii) ankle IMU position; (iii) length of the walkway; (iv) instructions given to participants
(Figure 1). Specifically, Xsens IMUs (unit weight 16 g, unit size 47 mm × 30 mm × 13 mm; MTw, Xsens,
NL) with a sampling frequency of 75 Hz were used in centre A and OPAL IMUs (unit weight 22 g,
unit size 48.5 mm × 36.5 mm × 13.5 mm; OPAL, APDM Inc., Portland, OR, USA) with a sampling
frequency of 128 Hz were used in centre B. The IMUs around both ankles were placed laterally in
centre A and frontally in centre B. PwMS were requested to walk at their maximum speed along a
30-meter straight corridor in centre A and at preferred comfortable speed along a 10-meter straight
corridor in centre B.
ȹ ȹ ȹ ȹ
ȹ ȹ ȹ ȹ
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Figure 1. Experimental protocols followed by centre A (red) and centre B (blue).
2.3. Data Processing
Data processing routines were developed in Matlab® (MATLAB R2019b, MathWorks, Inc., Natick,
MA, USA). A total of 33 IMU-based metrics were included in this analysis. IMU signals collected in
centre B were down sampled from 128 Hz to 75 Hz to match data from centre A, and the influence of
down sampling was investigated by comparing the outcome metrics from centre B as obtained before
and after the down sampling. Data from the lumbar IMU were reoriented to a horizontal-vertical
coordinate system [48] and filtered with a 10 Hz cut-off, zero phase, low-pass Butterworth filter.
The turning motion and resting breaks were detected and removed from IMU signals to isolate
steady-state walking bouts, whichwere used to compute themetrics of interest. The approach proposed
by Salarian, et al. [49] was adapted to determine 180◦ turns, which appear in the V component of
the lumbar angular velocity, ωz(t), as peaks of a given duration. The turning onset and offset were
identified from the trunk rotation angle around the V axis, θz(t), obtained after integrating the ωz(t)
signal. The turning components were evidenced in θz(t) as steep positive or negative gradients,
whereas walking components were evidenced as small oscillations round a flat line. Specifically, θz(t)
was first smoothed using a weighted least-squares linear regression. Abrupt change points and their
locations were then searched in θz(t) using a predefined Matlab® function based on the minimisation
of a linear computational cost function [50]. Resting breaks were automatically detected by checking in
2-s window increments if: (i) the norm of the lumbar IMU angular velocity was less than 0.5 rad/s;
(ii) the norm of the lumbar IMU acceleration was within ±10% of 9.81 m/s2 [51]. A 2-s window was
considered motionless if more than 50% of its samples fulfilled both criteria mentioned above.
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Twelve gait metrics were extracted from the angular velocities recorded from the ankle IMUs and
21 were extracted from the lumbar IMU accelerations. Following the suggestions of Lord, et al. [52] and
Buckley, et al. [53], these metrics were organised in independent gait domains (e.g., rhythm, variability,
asymmetry, intensity, stability, smoothness, symmetry, and regularity).
Initial and final foot contact instances, referred to as gait events (GE), were identified for each
steady-state walking bout as local minimum values of the ML angular velocity recorded from ankle
IMUs of both legs [54]. These minima occur just before and after the instant of maximumML angular
velocity. Once the GE were determined, stride, step, swing and stance durations (representing rhythm
domain) were separately estimated for left and right sides. Variability (i.e., within-subject combined
standard deviation of left and right; variability domain) and asymmetry (i.e., absolute difference
between themean of left and right time series; asymmetry domain) of thesemetrics were also computed,
applying the established formula in Galna, et al. [55] and Godfrey, et al. [56].
From processing the filtered acceleration signals in time and frequency domain, 21 additional
metrics, referred to as gait quality metrics [57], were separately extracted for each acceleration
component (AP, ML, and V): (i) intensity as the root mean square (RMS) of each acceleration component
around its mean value [44]; (ii) stability as the ratio of the RMS in a given direction to the RMS vector
magnitude [58]; (iii) smoothness as the RMS of the jerk [59]; (iv) symmetry represented by the harmonic
ratio (HR), defined as the ratio of the sum of the amplitudes of the in-phase harmonics to the sum of
the amplitudes of the out-of-phase harmonics [60,61]; (v) regularity as the ensemble of the following
three metrics obtained from the unbiased normalised autocorrelation [62]:
Step regularity = 1st peak o f (
1
N − |m|
N−|m|∑
i=1
x(i)·x(i + m)) (1)
Stride regularity = 2nd peak o f (
1
N − |m|
N−|m|∑
i=1
x(i)·x(i + m)) (2)
Regularity index =
∣∣∣Stride regularity− Step regularity
∣∣∣
mean(Stride regularity,Step regularity)
(3)
All metrics were calculated for the part of signals corresponding to the middle eight steps of each
pass along the corridor and then averaged over the whole trial. The choice of eight steps was due to
the maximum number of steps which subjects in centre B could walk in completely straight condition.
Since centre A adopted a three-times longer path, in order to process the same number of steps, only
one walking bout in every three was included for centre B.
2.4. Statistical Analysis
Statistical analyses were performed in R version 3.4.3 [63]. Participant characteristics from centre
A and centre B were compared using the independent Mann-Whitney U for age and EDSS scores and
Pearson’s chi-square for gender. Given the limited sample size and the non-normal distribution of most
of the investigated metrics (as a result of the Shapiro-Wilk test), non-parametric tests were performed.
The level of significance was taken at 5%. A Wilcoxon signed-rank test was performed to compare the
centre B metrics obtained from IMU data sampled at 128 Hz and those down-sampled at 75 Hz.
Between-day test-retest reliability of the metrics was evaluated for centre B through the intra-class
correlation coefficients (ICCs) with a 95% confidence interval (CI). ICCs were calculated using a
two-way random-effect model and absolute agreement (ICC2,k) [64]. An ICC lower than 0.39 was
classified as poor, an ICC between 0.40 and 0.59 as fair, an ICC between 0.60 and 0.74 as moderate, and
an ICC greater than 0.75 as excellent [65]. The minimum detectable changes (MDCs), representing
the smallest amount of change that can be considered above the bounds of the measurement error
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and/or within-subject variability, was also computed for each metric at the CI of 95%, according to
Equation (4):
MDC = 1.96·
√
2·SEM = 1.96·
√
2·SD·
√
1− ICC, (4)
where SEM is the standard error of the measurement and SD corresponds to the average of the standard
deviations from test and re-test sessions [66].
A Wilcoxon signed-rank test was used to determine if there was a median difference in centre B
metrics between the two sessions, whereas an independent Mann-Whitney U test was carried out to
compare IMU-based metrics from centre A and centre B.
In all the above tests, if the p-value was lower than 0.05, the null hypothesis (e.g., the two
population medians were identical) was rejected and the alternative hypothesis accepted. To avoid
misinterpretation of the p-values and to account for a type II error, the effect size (r) for non-parametric
tests was also calculated as follows:
r = z/
√
N (5)
where z is the z-score and N is the size of the study (i.e., the number of total observations) on which
z is based. Cohen [67] suggested thresholds of 0.1, 0.3, and 0.5 for small, medium, and large effect
sizes, respectively.
Median, inter-quartile range, minimum, and maximum values were finally calculated for
IMU-based metrics from centre A and centre B (both sessions).
3. Results
3.1. Effect of Sampling Frequency
The results of the comparison between the metrics calculated using the 128 Hz and 75 Hz sampling
frequencies are reported in Table 2. The HR, representative of the symmetry domain, was the only
metric that significantly differed between the two analyses.
Table 2. Effect of down-sampling of the acceleration and angular velocity signals on the investigated
gait metrics. Abbreviations: sampling frequency (FS), z-score (z), p-value (p), and effect size (r).
Domain Fs of 128 Hz Fs of 75 Hz z p r
Rhythm [s]
Stride duration 1.20 (1.01–1.74) 1.21 (1.01–1.74) −0.82 0.41 −0.16
Step duration 0.60 (0.51–0.87) 0.60 (0.50–0.87) 0.00 1.00 0.00
Stance duration 0.75 (0.61–1.18) 0.75 (0.61–1.18) −1.83 0.07 −0.36
Swing duration 0.44 (0.40–0.58) 0.44 (0.40–0.58) −1.85 0.06 −0.36
Variability [ms]
Stride duration 61 (32–100) 63 (32–98) −1.55 0.12 −0.30
Step duration 46 (20–69) 45 (20–68) −1.33 0.18 −0.26
Stance duration 65 (34–105) 65 (32–106) −0.18 0.86 −0.04
Swing duration 29 (23–74) 30 (21–76) −0.41 0.68 −0.08
Asymmetry [ms]
Stride duration 2 (0–7) 2 (1–7) −0.09 0.93 −0.02
Step duration 56 (0–238) 51 (0–242) −1.49 0.14 −0.29
Stance duration 61 (3–149) 69 (2–130) −1.58 0.11 −0.31
Swing duration 54 (1–155) 62 (0–138) −1.33 0.18 −0.26
Sensors 2020, 20, 79 7 of 17
Table 2. Cont.
Domain Fs of 128 Hz Fs of 75 Hz z p r
Intensity [m/s2]
Antero-Posterior 1.10 (0.80–1.96) 1.10 (0.80–1.95) −0.94 0.34 −0.19
Medio-Lateral 0.93 (0.65–1.41) 0.93 (0.65–1.41) −1.44 0.15 −0.28
Vertical 1.37 (0.76–3.16) 1.38 (0.75–3.20) −1.28 0.20 −0.25
Stability [–]
Antero-Posterior 0.41 (0.37–0.61) 0.41 (0.37–0.61) −0.30 0.77 −0.06
Medio-Lateral 0.34 (0.25–0.52) 0.34 (0.25–0.52) −0.89 0.37 −0.18
Vertical 0.58 (0.36–0.62) 0.58 (0.36–0.63) −0.29 0.77 −0.06
Smoothness [m/s3]
Antero-Posterior 13.97 (8.86–30.75) 13.95 (8.93–30.82) 0.00 1.00 0.00
Medio-Lateral 13.92 (10.13–28.61) 13.87 (10.19–28.45) −1.06 0.29 −0.21
Vertical 23.31 (11.06–48.81) 23.21 (10.89–49.38) −0.75 0.45 −0.15
Symmetry (HR) [–]
Antero-Posterior 2.94 (1.49–3.73) 2.89 (1.50–3.49) −2.32 0.02 * −0.45
Medio-Lateral 0.44 (0.32–0.56) 0.45 (0.32–0.56) −2.19 0.03 * −0.43
Vertical 3.01 (1.21–4.84) 2.94 (1.23–4.78) −3.01 0.00 * −0.59
Regularity [–]
Step regularity
Antero-Posterior 0.60 (0.20–0.85) 0.60 (0.20–0.84) −1.70 0.09 −0.33
Medio-Lateral −0.62 (−0.74–−0.37) −0.60 (−0.73–−0.38) −1.89 0.06 −0.37
Vertical 0.81 (0.32–0.95) 0.80 (0.32–0.94) −1.44 0.15 −0.28
Stride regularity
Anterior-Posterior 0.86 (0.50–0.93) 0.86 (0.50–0.92) 0.00 1.00 0.00
Medio-Lateral 0.77 (0.58–0.85) 0.75 (0.59–0.85) −1.67 0.09 −0.33
Vertical 0.86 (0.34–0.95) 0.86 (0.34–0.95) −1.80 0.07 −0.35
Regularity index
Antero-Posterior 0.37 (0.04–0.82) 0.37 (0.04–0.83) −1.10 0.27 −0.22
Medio-Lateral −0.20 (−0.70–−0.08) −0.20 (−0.66–−0.08) −0.41 0.68 −0.08
Vertical 0.11 (0.02–0.59) 0.11 (0.02–0.59) 0.00 1.00 0.00
Values are median (range). * p < 0.05.
3.2. Between-Day Test-Retest Reliability
ICC, SEM, and MDC values for between-day assessment are shown in Table 3 for each metric
estimated for pwMS from centre B who completed two testing visits. Overall, 17 out of 33 metrics
revealed excellent test-retest reliability (ICC: 0.93–0.98; 95% CI: 0.76–0.93), 11 metrics showed moderate
test-retest reliability (ICC: 0.88–0.92; 95% CI: 0.62–0.74), and only 5 metrics exhibited poor to fair
test-retest reliability with ICC values between 0.72 and 0.86 and 95% CI between 0.13 and 0.52.
The Wilcoxon signed-rank test showed no significant differences in any of the metrics between the two
sessions (Figure 2 and Table 4).
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Table 3. Intra-class correlation coefficients (ICC) with a 95% confidence interval (CI), standard error of
the measurement (SEM), and minimum detectable change (MDC) for the investigated gait metrics.
Domains ICC
95% CI
SEM MDC
Lower Upper
Rhythm [s]
Stride duration 0.97 0.90 0.99 0.04 0.10
Step duration 0.97 0.90 0.99 0.02 0.05
Stance duration 0.96 0.86 0.99 0.03 0.09
Swing duration 0.97 0.91 0.99 0.01 0.03
Variability [ms]
Stride duration 0.92 0.73 0.97 8 21
Step duration 0.92 0.74 0.98 5 13
Stance duration 0.94 0.80 0.98 6 18
Swing duration 0.95 0.85 0.99 4 11
Asymmetry [ms]
Stride duration 0.72 0.13 0.91 1 4
Step duration 0.98 0.93 0.99 10 29
Stance duration 0.90 0.67 0.97 12 33
Swing duration 0.89 0.62 0.97 13 36
Intensity [m/s2]
Antero-Posterior 0.97 0.90 0.99 0.06 0.16
Medio-Lateral 0.98 0.93 0.99 0.04 0.11
Vertical 0.97 0.92 0.99 0.10 0.29
Stability [–]
Antero-Posterior 0.93 0.78 0.98 0.02 0.05
Medio-Lateral 0.93 0.76 0.98 0.03 0.08
Vertical 0.91 0.69 0.97 0.03 0.09
Smoothness [m/s3]
Antero-Posterior 0.92 0.73 0.97 2.46 6.83
Medio-Lateral 0.93 0.79 0.98 1.55 4.29
Vertical 0.95 0.82 0.98 2.31 6.41
Symmetry (HR) [–]
Antero-Posterior 0.95 0.85 0.99 0.14 0.38
Medio-Lateral 0.75 0.15 0.92 0.04 0.10
Vertical 0.92 0.74 0.98 0.21 0.59
Regularity [–]
Step regularity
Antero-Posterior 0.91 0.70 0.97 0.07 0.19
Medio-Lateral 0.86 0.52 0.96 0.04 0.11
Vertical 0.97 0.92 0.99 0.04 0.10
Stride regularity
Antero-Posterior 0.88 0.64 0.96 0.05 0.13
Medio-Lateral 0.85 0.50 0.96 0.04 0.10
Vertical 0.93 0.77 0.98 0.04 0.10
Regularity index
Antero-Posterior 0.76 0.17 0.93 0.17 0.47
Medio-Lateral 0.88 0.62 0.96 0.06 0.17
Vertical 0.89 0.63 0.97 0.09 0.24
Inertial measurement unit (IMU)-based gait metrics with poor to fair test-retest reliability are presented in bold.
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Figure 2. Minimum, first quartile (q1), median, mean, third quartile (q3), and maximum values of
each IMU-based metrics relative to centre A (red) and centre B for between-day test-retest assessment
(blue empty boxplots and blue filled boxplots). Values larger than q1 + 1.5(q3 + q1) or smaller than
q1 − 1.5(q3 − q1) are considered outliers and are represented with crosses (+). * p < 0.05. Note that, for
graphical convenience, the absolute values have been depicted for the step regularity and regularity
index in the ML direction.
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Table 4. Descriptive statistics for the investigated gait metrics from centre B (session1 and session2),
including the z-score (z), p-value (p), and effect size (r).
Domain Centre B (session1) Centre B (session2) z p r
Rhythm [s]
Stride duration 1.21 (1.01–1.74) 1.20 (0.97–1.74) −0.70 0.48 −0.14
Step duration 0.60 (0.50–0.87) 0.60 (0.48–0.87) −0.56 0.58 −0.11
Stance duration 0.75 (0.61–1.18) 0.77 (0.59–1.18) −1.57 0.12 −0.31
Swing duration 0.44 (0.40–0.58) 0.45 (0.38–0.56) −1.99 0.05 −0.39
Variability [ms]
Stride duration 63 (32–98) 58 (27–124) −0.35 0.72 −0.07
Step duration 45 (20–68) 40 (18–83) −0.35 0.72 −0.07
Stance duration 65 (32–106) 52 (24–132) −0.03 0.97 −0.01
Swing duration 30 (21–76) 28 (9–97) −0.53 0.60 −0.10
Asymmetry [ms]
Stride duration 2 (1–7) 4 (0–7) −1.34 0.18 −0.26
Step duration 51 (0–242) 65 (4–245) −1.30 0.20 −0.25
Stance duration 69 (2–130) 61 (10–104) −0.52 0.60 −0.10
Swing duration 62 (0–138) 61 (12–109) −0.38 0.70 −0.08
Intensity [m/s2]
Antero-Posterior 1.10 (0.80–1.95) 1.07 (0.76–2.04) −1.22 0.22 −0.24
Medio-Lateral 0.93 (0.65–1.41) 0.93 (0.53–1.42) −0.08 0.94 −0.02
Vertical 1.38 (0.75–3.20) 1.43 (0.68–3.14) −0.38 0.70 −0.08
Stability [–]
Antero-Posterior 0.41 (0.37–0.61) 0.43 (0.35–0.64) −0.28 0.78 −0.05
Medio-Lateral 0.34 (0.25–0.52) 0.32 (0.24–0.56) 0.00 1.00 0.00
Vertical 0.58 (0.36–0.63) 0.57 (0.28–0.69) −0.27 0.79 −0.05
Smoothness [m/s3]
Antero-Posterior 13.95 (8.93–30.82) 17.11 (2.76–37.32) −1.17 0.24 −0.23
Medio-Lateral 13.87 (10.19–28.45) 13.42 (8.04–26.07) −1.24 0.22 −0.24
Vertical 23.21 (10.89–49.38) 23.43 (10.67–50.74) −0.41 0.68 −0.08
Symmetry (HR) [–]
Antero-Posterior 2.89 (1.50–3.49) 2.64 (1.62–3.54) −0.31 0.75 −0.06
Medio-Lateral 0.45 (0.32–0.56) 0.46 (0.34–0.59) −0.82 0.41 −0.16
Vertical 2.94 (1.23–4.78) 2.75 (1.45–4.19) −0.51 0.61 −0.10
Regularity [–]
Step regularity
Antero-Posterior 0.60 (0.20–0.84) 0.57 (0.26–0.93) −0.12 0.91 −0.02
Medio-Lateral −0.60 (−0.73–−0.38) −0.58 (−0.71–−0.42) −0.07 0.94 −0.01
Vertical 0.80 (0.32–0.94) 0.78 (0.22–0.96) −1.26 0.21 −0.25
Stride regularity
Anterior-Posterior 0.86 (0.50–0.92) 0.87 (0.33–0.92) −0.98 0.33 −0.19
Medio-Lateral 0.75 (0.59–0.85) 0.73 (0.55–0.88) −0.03 0.97 −0.01
Vertical 0.86 (0.34–0.95) 0.83 (0.44–0.91) −0.52 0.60 −0.10
Regularity index
Antero-Posterior 0.37 (0.04–0.83) 0.34 (0.01–1.09) −0.04 0.97 −0.01
Medio-Lateral −0.20 (−0.66–−0.08) −0.27 (−0.65–−0.04) −0.14 0.89 −0.03
Vertical 0.11 (0.02–0.59) 0.14 (0.02–1.00) −0.43 0.67 −0.08
Values are median (range). * p < 0.05.
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3.3. Between-Centre Differences
As expected, the comparison between centre A and centre B via the independent Mann-Whitney
U test highlighted significant differences for all the temporal metrics (Figure 2 and Table 5; rhythm
domain), except for swing duration. Apart from asymmetry of step duration and asymmetry of swing
duration, variability and asymmetry of the temporal metrics were significantly lower in centre A
compared to centre B (Figure 2 and Table 5; variability and asymmetry domain). However, even
though the difference in asymmetry of swing duration between the two centres was non-significant
(U = 48.0; p = 0.06), a fairly moderate effect size was found for this specific metric (r = 0.37). Conversely,
a consistency between the two centres was found for 18 out of 21 metrics extracted from acceleration
signals (Figure 2 and Table 5; intensity, stability, smoothness, symmetry, and regularity domains). Only
the differences in the regularity index in the ML direction and in the HR in the AP and ML directions
were proved statistically significant between centre A and centre B (Figure 2 and Table 5).
Table 5. Descriptive statistics for the investigated gait metrics from centre A and centre B (session1),
including the Mann-Whitney U (MWU) statistic, p-value (p), and effect size (r).
Domain Centre A Centre B U p r
Rhythm [s]
Stride duration 1.03 (0.92–1.68) 1.21 (1.01–1.74) 43.5 0.04 * 0.41
Step duration 0.51 (0.46–0.84) 0.60 (0.50–0.87) 44.0 0.04 * 0.41
Stance duration 0.66 (0.52–1.12) 0.75 (0.61–1.18) 40.0 0.02 * 0.45
Swing duration 0.43 (0.37–0.56) 0.44 (0.40–0.58) 57.0 0.17 0.28
Variability [ms]
Stride duration 32 (23–74) 63 (32–98) 26.0 0.00 * 0.59
Step duration 21 (14–45) 45 (20–68) 27.5 0.00 * 0.57
Stance duration 28 (17–68) 65 (32–106) 30.0 0.01 * 0.55
Swing duration 19 (12–41) 30 (21–76) 33.0 0.01 * 0.52
Asymmetry [ms]
Stride duration 1 (0–4) 2 (1–7) 45.0 0.04 * 0.40
Step duration 19 (1–138) 51 (0–242) 68.0 0.40 0.17
Stance duration 17 (0–123) 69 (2–130) 46.0 0.04 * 0.39
Swing duration 17 (1–122) 62 (0–138) 48.0 0.06 0.37
Intensity [m/s2]
Antero-Posterior 1.30 (0.81–1.80) 1.10 (0.80–1.95) 68.0 0.41 0.17
Medio-Lateral 1.17 (0.53–1.69) 0.93 (0.65–1.41) 62.0 0.26 0.23
Vertical 2.17 (0.73–2.62) 1.38 (0.75–3.20) 59.5 0.21 0.25
Stability [–]
Antero-Posterior 0.40 (0.28–0.68) 0.41 (0.37–0.61) 69.0 0.44 0.16
Medio-Lateral 0.38 (0.23–0.48) 0.34 (0.25–0.52) 83.0 0.96 0.02
Vertical 0.57 (0.47–0.75) 0.58 (0.36–0.63) 72.5 0.55 0.12
Smoothness [m/s3]
Antero-Posterior 19.68 (8.56–31.85) 13.95 (8.93–30.82) 82.0 0.92 0.03
Medio-Lateral 24.01 (7.04–35.54) 13.87 (10.19–28.45) 52.5 0.11 0.32
Vertical 33.90 (11.56–42.39) 23.21 (10.89–49.38) 59.0 0.20 0.26
Symmetry (HR) [–]
Antero-Posterior 2.04 (1.36–3.54) 2.89 (1.50–3.49) 43.5 0.04 * 0.41
Medio-Lateral 0.57 (0.44–0.91) 0.45 (0.32–0.56) 14.0 0.00 * 0.71
Vertical 2.35 (1.39–3.89) 2.94 (1.23–4.78) 52.5 0.11 0.32
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Table 5. Cont.
Domain Centre A Centre B U p r
Regularity [–]
Step regularity
Antero-Posterior 0.75 (0.14–0.95) 0.60 (0.20–0.84) 55.5 0.14 0.29
Medio-Lateral −0.66 (−0.88–−0.23) −0.60 (−0.73–−0.38) 63.0 0.28 0.22
Vertical 0.89 (0.37–0.95) 0.80 (0.32–0.94) 51.5 0.10 0.33
Stride regularity
Anterior-Posterior 0.86 (0.67–0.93) 0.86 (0.50–0.92) 81.5 0.90 0.03
Medio-Lateral 0.69 (0.45–0.87) 0.75 (0.59–0.85) 63.0 0.28 0.22
Vertical 0.89 (0.59–0.96) 0.86 (0.34–0.95) 72.5 0.55 0.12
Regularity index
Antero-Posterior 0.08 (0.03–1.46) 0.37 (0.04–0.83) 50.0 0.08 0.35
Medio-Lateral −0.10 (−0.98–−0.05) −0.20 (−0.66–−0.08) 40.5 0.03 * 0.44
Vertical 0.05 (0.02–0.74) 0.11 (0.02–0.59) 51.5 0.09 0.33
Values are median (range). * p < 0.05.
4. Discussion
This study aimed to identify comparable gait metrics as quantified from IMU data measured from
two different hospital settings on two matched cohorts of pwMS (13 pwMS for each centre, Table 1),
under the hypothesis that those metrics associated with the overall balance control and coordination
of gait (i.e., gait quality metrics) would be robust, even when obtained from different experimental
protocols. Reported results overall corroborated this assumption and showed that between-centre
differences for most of these metrics were comparable to those obtained by the same centre in two
different sessions.
The small sample size, resulting from the attempt of maximising the cohort match, is certainly
a limitation of this study. It is worth noting, in fact, that while some of the investigated gait metrics
in centre A (e.g., asymmetry of swing duration from asymmetry domain and regularity index from
regularity domain) did not differ significantly from those in centre B, an observed medium effect size
suggested the opposite might hold true (Table 5). This is indeed likely to be due to the small sample
size and possibly due to the higher inter-subject variability observed in centre B.
Since MS is well known for heterogeneity of symptoms, high day-to-day fluctuations, and a large
variability in its course [68], care must be taken before generalising our findings to all pwMS with
different levels of gait impairment. Another limitation of this study might lie in the fact that patients
recruited by the two centres differed in the subtypes of MS. Nonetheless, Dujmovic, et al. [69] showed
that the altered gait pattern in pwMS did not depend on the disease phenotype. Additional studies are
of course needed to further investigate this aspect.
The comparison between centre A and centre B implied down-sampling the data from the latter.
As expected, this affected only the calculation of HR, which is the only metric based on frequency
analysis. In particular, changing sampling frequency from 128 Hz to 75 Hz led to decreased values in
the AP and V directions and increased values in the ML direction (Table 2). This is in line with what
was previously reported by Riva, et al. [35].
Moderate to excellent between-day test-retest reliability was observed for 28 out of 33 IMU-based
metrics with few exceptions, which exhibited poor to fair reliability (Table 3). Additionally, all the
investigated metrics were not significantly different between the two sessions (Figure 2 and Table 4),
even if some of these results (swing duration in particular) should be interpreted with care, due to the
medium effect size. These findings confirmed that sensor-based gait analysis is a reliable tool in pwMS,
as also reported in previous test-retest studies on pwMS [34].
Walking speed clearly affected the gait outcomes. In particular, the gait metrics representative of
rhythm, variability, and asymmetry domains were evidently lower in centre A compared to centre
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B (Figure 2 and Table 5) due to different instructions given to the participants in terms of walking
speed (i.e., walk at maximum speed versus walk at self-selected speed). This finding is in agreement
with previous studies on pwMS [28] and on people with other neurological conditions, such as
Parkinson’s disease [70], which observed a reduction of the above metrics with increasing walking
speed. The shorter length of the walkway used in centre B could also have contributed to these
differences. In fact, Storm, et al. [22] demonstrated that rhythm and variability metrics decreased
when walking longer distances (e.g., lower stride duration and lower variability of stride duration).
However, the data available for our study did not allow us to separate walking speed and path effects,
and further studies should hence be performed to this purpose.
Unlike the temporal metrics, the gait quality metrics appeared to be robust with respect to the
notable differences in the experimental gait protocols adopted by the two centres. Among these metrics,
in fact, only differences in the regularity index in the ML direction and the HR (representative of
symmetry domain) in the AP and ML directions were found to be statistically significant between
centre A and centre B (Figure 2 and Table 5). Again, this specific result could be explained both by the
different walking speed and by the different lengths of the walkway in the two centres. Indeed, an
association between walking speed and HR has been previously showed, both in healthy young [43,44]
and older subjects [39]. These authors observed that the HR increased at the self-selected comfortable
walking speed and decreased at slower and faster speeds. A similar trend emerged from our analysis,
except for the HR in the ML direction, but this specific metric should be handled with care due to
its observed low test-retest reliability (Table 3). The low number of steps (i.e., eight steps) used for
calculating the HR for each walking bout might also have contributed to reduce robustness and
reliability of this metric [57,71]. However, this choice was imposed by the reduced length of the
corridor in centre B. Testing the participants along a shorter path also implied a higher number of turns
over the 6 min, resulting in a minor validity of the HR as showed in the research by Riva, et al. [35] and
by Brach, et al. [40].
While further studies are of course needed to fully validate this hypothesis, our results suggest
that, in agreement with what is already reported for other neurological diseases, such as Parkinson’s
disease [53], the gait quality metrics extracted from the upper body accelerations should not be
considered as a simple reflection of gait spatio-temporal features and might bring complementary
informative content in quantifying patients’ gait ability. Additionally, these metrics have been recently
shown to be sensitive to fatigue and pathology progression in pwMS [72] and, as such, they are
promising candidates for quantification of disease progression and rehabilitation interventions in
these patients.
5. Conclusions
In conclusion, this pragmatic study showed consistency in the gait metrics from two matched
groups of pwMS, even when they were assessed in two different hospitals and under notably different
gait testing conditions. The identification of such robust gait metrics opens the possibility of comparing
retrospective data and paves the way for reliable multi-centre studies to be conducted in routine
hospital settings rather than in specialised gait research laboratories. This is essential to allow an
increase of sample size and statistical power of clinical trials in which rehabilitation interventions need
to be quantitatively assessed.
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